| Dokumentenart: | Artikel | ||||
|---|---|---|---|---|---|
| Open Access Art: | DEAL (Springer) - Nicht UR | ||||
| Titel eines Journals oder einer Zeitschrift: | EJNMMI Research | ||||
| Verlag: | SPRINGER | ||||
| Ort der Veröffentlichung: | NEW YORK | ||||
| Band: | 11 | ||||
| Nummer des Zeitschriftenheftes oder des Kapitels: | 1 | ||||
| Datum: | 2021 | ||||
| Institutionen: | Medizin > Abteilung für Neuropathologie | ||||
| Identifikationsnummer: |
| ||||
| Stichwörter / Keywords: | CENTRAL-NERVOUS-SYSTEM; DYNAMIC F-18-FET PET; LOW-GRADE GLIOMA; RESPONSE ASSESSMENT; PROGNOSTIC-SIGNIFICANCE; LUNG; C-11-METHIONINE; NEUROONCOLOGY; ADENOCARCINOMA; ASCT2; LAT1; FET PET; Glioma; Molecular imaging | ||||
| Dewey-Dezimal-Klassifikation: | 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin | ||||
| Status: | Veröffentlicht | ||||
| Begutachtet: | Ja, diese Version wurde begutachtet | ||||
| An der Universität Regensburg entstanden: | Ja | ||||
| Dokumenten-ID: | 56456 |
Web of ScienceZusammenfassung
Background O-(2-[F-18]-fluoroethyl)-L-tyrosine (F-18-FET) is a highly sensitive PET tracer for glioma imaging, and its uptake is suggested to be driven by an overexpression of the L-type amino-acid transporter 1 (LAT1). However, 30% of low- and 5% of high-grade gliomas do not present enhanced F-18-FET uptake at primary diagnosis ("F-18-FET-negative gliomas") and the pathophysiologic basis for ...
Zusammenfassung
Background O-(2-[F-18]-fluoroethyl)-L-tyrosine (F-18-FET) is a highly sensitive PET tracer for glioma imaging, and its uptake is suggested to be driven by an overexpression of the L-type amino-acid transporter 1 (LAT1). However, 30% of low- and 5% of high-grade gliomas do not present enhanced F-18-FET uptake at primary diagnosis ("F-18-FET-negative gliomas") and the pathophysiologic basis for this phenomenon remains unclear. The aim of this study was to determine the expression of LAT1 in a homogeneous group of newly diagnosed F-18-FET-negative gliomas and to compare them to a matched group of F-18-FET-positive gliomas. Forty newly diagnosed IDH-mutant astrocytomas without 1p/19q codeletion were evaluated (n = 20 F-18-FET-negative (tumour-to-background ratio (TBR) < 1.6), n = 20 F-18-FET-positive gliomas (TBR > 1.6)). LAT1 immunohistochemistry (IHC) was performed using SLC7A5/LAT1 antibody. The percentage of LAT1-positive tumour cells (%) and the staining intensity (range 0-2) were multiplied to an overall score (H-score; range 0-200) and correlated to PET findings as well as progression-free survival (PFS). Results IHC staining of LAT1 expression was positive in both, F-18-FET-positive as well as F-18-FET-negative gliomas. No differences were found between the F-18-FET-negative and F-18-FET-positive group with regard to percentage of LAT1-positive tumour cells, staining intensity or H-score. Interestingly, the LAT1 expression showed a significant negative correlation with the PFS (p = 0.031), whereas no significant correlation was found for TBRmax, neither in the overall group nor in the F-18-FET-positive group only (p = 0.651 and p = 0.140). Conclusion Although LAT1 is reported to mediate the uptake of F-18-FET into tumour cells, the levels of LAT1 expression do not correlate with the levels of F-18-FET uptake in IDH-mutant astrocytomas. In particular, the lack of tracer uptake in F-18-FET-negative gliomas cannot be explained by a reduced LAT1 expression. A higher LAT1 expression in IDH-mutant astrocytomas seems to be associated with a short PFS. Further studies regarding mechanisms influencing the uptake of F-18-FET are necessary.
Metadaten zuletzt geändert: 29 Feb 2024 12:28
Altmetric